바이러스 벡터 제조 시장 - 세계 산업 규모, 점유율, 동향, 기회, 예측 : 벡터 유형별, 워크플로우별, 용도별, 최종사용자별, 지역별, 경쟁별(2020-2030년)
Viral Vector Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Vector Type, By Workflow, By Application, By End User, By Region and Competition, 2020-2030F
바이러스 벡터 제조 세계 시장은 2024년에 67억 1,000만 달러로 평가되었으며, 2030년에는 159억 2,000만 달러에 달할 것으로 예측되며, 예측 기간 동안 CAGR 15.45%로 성장할 것으로 예측됩니다.
바이러스 벡터 제조는 치료 또는 연구 목적으로 표적 세포에 유전 물질을 전달하기 위한 운반체로 사용되는 인공 바이러스의 개발을 포함합니다. 이러한 벡터는 유전자 치료, 유전자 편집, 백신 개발에 도움이 되고 있으며, 유전자 질환 및 암 치료에 정확성을 제공하고 있습니다. 이 과정에는 병원성을 제거하고 치료 유전자를 삽입하기 위해 바이러스 유전체를 변형하는 과정이 포함됩니다. 주요 바이러스 벡터에는 아데노 부속 바이러스(AAV), 렌티바이러스, 아데노바이러스, 아데노바이러스, 레트로바이러스 등이 있으며, 각각 의도된 용도, 표적 세포의 종류, 필요한 발현 프로파일에 따라 선택됩니다. 승인된 유전자 치료제의 성공과 R&D 투자 증가는 고품질의 확장 가능한 바이러스 벡터 제조에 대한 수요를 가속화하여 이 분야의 괄목할 만한 성장을 주도하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
67억 1,000만 달러 |
| 시장 규모 : 2030년 |
159억 2,000만 달러 |
| CAGR : 2025-2030년 |
15.45% |
| 급성장 부문 |
아데노 부속 바이러스 벡터 |
| 최대 시장 |
북미 |
시장 촉진요인
바이러스 벡터 생산의 선구적인 임상적 성공
주요 시장 과제
확장성과 상업화
주요 시장 동향
제조 공정 최적화
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 바이러스 벡터 제조 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 벡터 유형별(아데노바이러스, AAV, 렌티바이러스, 레트로바이러스 등)
- 워크플로우별(업스트림 처리, 벡터 증폭 및 확장, 벡터 회수/수확, 다운스트림 처리, 정제, 충전 마감)
- 용도별(유전자·세포 치료 개발, 백신 개발, 바이오의약품·Drug Discovery, 바이오메디컬 연구)
- 최종사용자별(제약회사, 바이오의약품 회사, 연구기관)
- 기업별(2024)
- 지역별
- 시장 맵
제6장 북미의 바이러스 벡터 제조 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 바이러스 벡터 제조 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 바이러스 벡터 제조 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
- 중국 바이러스 벡터 제조 시장
- 인도 바이러스 벡터 제조 시장
- 한국 바이러스 벡터 제조 시장
- 일본 바이러스 벡터 제조 시장
- 호주 바이러스 벡터 제조 시장
제9장 남미의 바이러스 벡터 제조 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 바이러스 벡터 제조 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
제11장 시장 역학
제12장 시장 동향과 발전
제13장 PESTEL 분석
제14장 Porter's Five Forces 분석
- 업계내 경쟁
- 신규 참여의 가능성
- 공급업체의 능력
- 고객의 능력
- 대체품의 위협
제15장 경쟁 구도
- Merck KGaA
- FUJIFILM Diosynth Biotechnologies U.S.A
- Cobra Biologics Ltd.
- Thermofisher Scientific Inc.
- Waisman Biomanufacturing
- Genezen Laboratories
- Advanced BioScience Laboratories, Inc.(ABL inc.)
- Novasep Holding s.a.s.
- Orgenesis Biotech Israel Ltd(formerly ATVIO Biotech ltd.)
- Takara Bio Inc.
제16장 전략적 제안
제17장 조사 회사 소개 및 면책사항
ksm
The Global Viral Vector Production Market was valued at USD 6.71 billion in 2024 and is anticipated to reach USD 15.92 billion by 2030, growing at a CAGR of 15.45% during the forecast period. Viral vector production involves the development of engineered viruses used as carriers to deliver genetic material into targeted cells for therapeutic or research purposes. These vectors are instrumental in gene therapy, gene editing, and vaccine development, offering precision in treating genetic disorders and cancers. The process entails modifying viral genomes to eliminate pathogenic properties and incorporate therapeutic genes. Key viral vectors include adeno-associated viruses (AAV), lentiviruses, adenoviruses, and retroviruses, each selected based on the intended application, target cell type, and required expression profile. The growing success of approved gene therapies and increasing R&D investments are accelerating demand for high-quality, scalable viral vector manufacturing, driving significant growth in this segment.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 6.71 Billion |
| Market Size 2030 | USD 15.92 Billion |
| CAGR 2025-2030 | 15.45% |
| Fastest Growing Segment | Adeno-Associated Virus Vectors |
| Largest Market | North America |
Key Market Drivers
Pioneering Clinical Success of Viral Vector Production
The clinical success of gene therapies leveraging viral vectors has played a critical role in driving market growth. Breakthroughs such as Luxturna, approved by the FDA for treating Leber congenital amaurosis (LCA), and Zolgensma for spinal muscular atrophy (SMA), underscore the transformative potential of viral vector-based treatments. Zolgensma alone has treated over 3,000 patients globally as of 2023. Additionally, promising advancements in hemophilia B treatments, utilizing AAV vectors to restore clotting factor IX levels, highlight the clinical viability of these delivery tools. Lentiviral vectors have also been widely adopted in CAR-T cell therapies targeting blood cancers. These successes demonstrate the therapeutic efficacy, safety, and long-term benefits of viral vectors, prompting increased investment and adoption across both academic and commercial sectors.
Key Market Challenges
Scalability and Commercialization
Scaling up viral vector production for commercial use poses significant operational and financial hurdles. Transitioning from lab-scale to large-scale manufacturing requires overcoming challenges such as maintaining yield consistency, optimizing cell culture conditions, and controlling vector integrity under scaled processes. High-yield production must address issues related to oxygen transfer, nutrient delivery, and shear stress in bioreactors. Additionally, ensuring quality and stability of viral vectors during purification and fill-finish steps is essential but complex. Building compliant manufacturing facilities requires large capital investment and adherence to strict regulatory standards. These scale-related constraints delay commercialization timelines, increase production costs, and limit patient access to advanced therapies, especially when demand accelerates.
Key Market Trends
Manufacturing Process Optimization
Process optimization is a critical trend shaping the viral vector production landscape. Industry players are focusing on increasing yield, consistency, and scalability through innovations in upstream and downstream workflows. Efforts include enhancing cell line productivity, refining transfection protocols, and automating quality control. Manufacturers are standardizing production processes to ensure reproducibility across facilities, which aids in regulatory compliance and technology transfer. Moreover, improvements in purification and fill-finish steps are helping reduce impurities and boost product quality. Environmentally sustainable manufacturing approaches-such as reducing waste and energy usage-are also gaining prominence. These optimizations not only lower production costs but also ensure that therapies reach patients more efficiently and reliably.
Key Market Players
- Merck KGaA
- FUJIFILM Diosynth Biotechnologies U.S.A
- Cobra Biologics Ltd.
- Thermo Fisher Scientific Inc.
- Waisman Biomanufacturing
- Genezen Laboratories
- Advanced BioScience Laboratories, Inc. (ABL Inc.)
- Novasep Holding S.A.S.
- Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech Ltd.)
- Takara Bio Inc.
Report Scope:
In this report, the Global Viral Vector Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Viral Vector Production Market, By Vector Type:
- Adenovirus
- AAV
- Lentivirus
- Retrovirus
- Others
Viral Vector Production Market, By Workflow:
- Upstream Processing
- Vector Amplification and Expansion
- Vector Recovery/Harvesting
- Downstream Processing
- Purification
- Fill Finish
Viral Vector Production Market, By Application:
- Gene and Cell Therapy Development
- Vaccine Development
- Biopharmaceutical and Pharmaceutical Discovery
- Biomedical Research
Viral Vector Production Market, By End User:
- Pharmaceutical and Biopharmaceutical Companies
- Research Institutes
Viral Vector Production Market, By Region:
- North America
- United States
- Canada
- Mexico
- Asia-Pacific
- China
- India
- South Korea
- Australia
- Japan
- Europe
- Germany
- France
- United Kingdom
- Spain
- Italy
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Viral Vector Production Market.
Available Customizations:
Global Viral Vector Production Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Viral Vector Production Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Vector Type (Adenovirus, AAV, Lentivirus, Retrovirus, others)
- 5.2.2. By Workflow (Upstream Processing, Vector amplification and expansion, Vector recovery/harvesting, Downstream Processing, Purification, Fill finish)
- 5.2.3. By Application (Gene and Cell Therapy Development, Vaccine Development, Biopharmaceutical and Pharmaceutical Discovery, Biomedical Research)
- 5.2.4. By End User (Pharmaceutical and Biopharmaceutical Companies, Research Institutes)
- 5.2.5. By Company (2024)
- 5.2.6. By Region
- 5.3. Market Map
6. North America Viral Vector Production Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Vector Type
- 6.2.2. By Workflow
- 6.2.3. By Application
- 6.2.4. By End User
- 6.2.5. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Viral Vector Production Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Vector Type
- 6.3.1.2.2. By Workflow
- 6.3.1.2.3. By Application
- 6.3.1.2.4. By End User
- 6.3.2. Mexico Viral Vector Production Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Vector Type
- 6.3.2.2.2. By Workflow
- 6.3.2.2.3. By Application
- 6.3.2.2.4. By End User
- 6.3.3. Canada Viral Vector Production Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Vector Type
- 6.3.3.2.2. By Workflow
- 6.3.3.2.3. By Application
- 6.3.3.2.4. By End User
7. Europe Viral Vector Production Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Vector Type
- 7.2.2. By Workflow
- 7.2.3. By Application
- 7.2.4. By End User
- 7.2.5. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. France Viral Vector Production Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Vector Type
- 7.3.1.2.2. By Workflow
- 7.3.1.2.3. By Application
- 7.3.1.2.4. By End User
- 7.3.2. Germany Viral Vector Production Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Vector Type
- 7.3.2.2.2. By Workflow
- 7.3.2.2.3. By Application
- 7.3.2.2.4. By End User
- 7.3.3. United Kingdom Viral Vector Production Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Vector Type
- 7.3.3.2.2. By Workflow
- 7.3.3.2.3. By Application
- 7.3.3.2.4. By End User
- 7.3.4. Italy Viral Vector Production Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Vector Type
- 7.3.4.2.2. By Workflow
- 7.3.4.2.3. By Application
- 7.3.4.2.4. By End User
- 7.3.5. Spain Viral Vector Production Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Vector Type
- 7.3.5.2.2. By Workflow
- 7.3.5.2.3. By Application
- 7.3.5.2.4. By End User
8. Asia-Pacific Viral Vector Production Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Vector Type
- 8.2.2. By Workflow
- 8.2.3. By Application
- 8.2.4. By End User
- 8.2.5. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Viral Vector Production Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Vector Type
- 8.3.1.2.2. By Workflow
- 8.3.1.2.3. By Application
- 8.3.1.2.4. By End User
- 8.3.2. India Viral Vector Production Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Vector Type
- 8.3.2.2.2. By Workflow
- 8.3.2.2.3. By Application
- 8.3.2.2.4. By End User
- 8.3.3. South Korea Viral Vector Production Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Vector Type
- 8.3.3.2.2. By Workflow
- 8.3.3.2.3. By Application
- 8.3.3.2.4. By End User
- 8.3.4. Japan Viral Vector Production Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Vector Type
- 8.3.4.2.2. By Workflow
- 8.3.4.2.3. By Application
- 8.3.4.2.4. By End User
- 8.3.5. Australia Viral Vector Production Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Vector Type
- 8.3.5.2.2. By Workflow
- 8.3.5.2.3. By Application
- 8.3.5.2.4. By End User
9. South America Viral Vector Production Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Vector Type
- 9.2.2. By Workflow
- 9.2.3. By Application
- 9.2.4. By End User
- 9.2.5. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Viral Vector Production Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Vector Type
- 9.3.1.2.2. By Workflow
- 9.3.1.2.3. By Application
- 9.3.1.2.4. By End User
- 9.3.2. Argentina Viral Vector Production Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Vector Type
- 9.3.2.2.2. By Workflow
- 9.3.2.2.3. By Application
- 9.3.2.2.4. By End User
- 9.3.3. Colombia Viral Vector Production Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Vector Type
- 9.3.3.2.2. By Workflow
- 9.3.3.2.3. By Application
- 9.3.3.2.4. By End User
10. Middle East and Africa Viral Vector Production Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Vector Type
- 10.2.2. By Workflow
- 10.2.3. By Application
- 10.2.4. By End User
- 10.2.5. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Viral Vector Production Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Vector Type
- 10.3.1.2.2. By Workflow
- 10.3.1.2.3. By Application
- 10.3.1.2.4. By End User
- 10.3.2. Saudi Arabia Viral Vector Production Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Vector Type
- 10.3.2.2.2. By Workflow
- 10.3.2.2.3. By Application
- 10.3.2.2.4. By End User
- 10.3.3. UAE Viral Vector Production Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Vector Type
- 10.3.3.2.2. By Workflow
- 10.3.3.2.3. By Application
- 10.3.3.2.4. By End User
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Developments
- 12.2. Product Launches
- 12.3. Mergers & Acquisitions
13. PESTLE Analysis
14. Porter's Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Product
15. Competitive Landscape
- 15.1. Merck KGaA
- 15.1.1. Business Overview
- 15.1.2. Company Snapshot
- 15.1.3. Products & Services
- 15.1.4. Financials (As Reported)
- 15.1.5. Recent Developments
- 15.1.6. Key Personnel Details
- 15.1.7. SWOT Analysis
- 15.2. FUJIFILM Diosynth Biotechnologies U.S.A
- 15.3. Cobra Biologics Ltd.
- 15.4. Thermofisher Scientific Inc.
- 15.5. Waisman Biomanufacturing
- 15.6. Genezen Laboratories
- 15.7. Advanced BioScience Laboratories, Inc. (ABL inc.)
- 15.8. Novasep Holding s.a.s.
- 15.9. Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
- 15.10. Takara Bio Inc.
16. Strategic Recommendations
17. About Us & Disclaimer
